Alectinib, also known as AF802, or CH5424802 or RO5424802, is a potent, selective, and orally available ALK inhibitor with a unique chemical scaffold, showing preferential antitumor activity against cancers with gene alterations of ALK, such as nonsmall cell lung cancer (NSCLC) cells expressing EML4-ALK fusion and anaplastic large-cell lymphoma (ALCL) cells expressing NPM-ALK fusion in vitro and in vivo. CH5424802 inhibited ALK L1196M, which corresponds to the gatekeeper mutation conferring common resistance to kinase inhibitors, and blocked EML4-ALK L1196M-driven cell growth. Alectinib was approved in Dec. 2015.
Xu, Xuenong. Alectinib preparation method. CN 104402862. (Assignee Suzhou Miracpharma Technology Co., Ltd., Peop. Rep. China)
Liu, Ye; Xiong, Yuanqiang. Process for the preparation of alectinib from 6-bromo-3,4-dihydro-2(1H)-naphthalenone. CN 105777710. (Assignee Hunan Ouya Biological Co., Ltd., Peop. Rep. China)
Chen, Peng; Zhao, Guolei. Process for preparation of Alectinib. CN 106518842. (Assignee Beijing Wanquan Dezhong Pharmaceutical Biotechnology Co., Ltd., Peop. Rep. China)
Chen, Jian; Huang, Wei; Zhong, Yunjian. Preparation method of alectinib from 2-(4-bromo-3-hydroxyphenyl)acetate. CN 106995433. (Assignee Hunan Boaode Biopharmaceutical Technology Development Co., Ltd., Peop. Rep. China)
Ning, Ting; Tong, Ming; Li, Tao. Preparation method of alectinib. CN 107033125. (Assignee Hunan Boaode Biopharmaceutical Technology Development Co., Ltd., Peop. Rep. China)
Lin, Kaichao; Huang, Wei; Zhang, Jianguo. Method for preparing alectinib. CN 107129488. (Assignee Hunan Boaode Biopharmaceutical Technology Development Co., Ltd., Peop. Rep. China)
Dong, Dandan. Method for preparation of Alectinib. CN 107987056.
Furumoto, Kentaro; Shiraki, Koji; Hirayama, Tomoaki. Composition containing tetracyclic compound and dissolution aid. WO 2012023597. (Assignee Chugai Seiyaku Kabushiki Kaisha, Japan)
Xu, Xuenong. Alectinib preparation method. WO 2016074532. (Assignee Suzhou Miracpharma Technology Co., Ltd., Peop. Rep. China; Zheren Pharmaceutical Nanjing Co., Ltd.)
Kinoshita, Kazutomo; Asoh, Kohsuke; Furuichi, Noriyuki; Ito, Toshiya; Kawada, Hatsuo; Hara, Sousuke; Ohwada, Jun; Miyagi, Takuho; Kobayashi, Takamitsu; Takanashi, Kenji; Tsukaguchi, Toshiyuki; Sakamoto, Hiroshi; Tsukuda, Takuo; Oikawa, Nobuhiro. Design and synthesis of a highly selective, orally active and potent anaplastic lymphoma kinase inhibitor (CH5424802). Bioorganic & Medicinal Chemistry. Volume 20. Issue 3. Pages 1271-1280. 2012.
